Vistagen Therapeutics, Inc. Common Stock

Kuehn Law is investigating whether officers and directors of Vistagen Therapeutics breached fiduciary duties by misrepresenting or failing to disclose risks in their Social Anxiety Disorder clinical trials. The firm alleges insiders downplayed known issues with public speaking challenge endpoints, including elevated placebo responses and site var...

A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) alleging that defendants made materially false and misleading statements regarding the company's drug fasedienol and its Phase 3 PALISADE-3 clinical trial. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligib...

A class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud, claiming the company made materially false and misleading statements about its fasedienol drug candidate and the PALISADE-3 clinical trial while concealing adverse data. Investors who purchased Vistagen securities between April 1, 2024 and December 1...

The Schall Law Firm is seeking investors who purchased Vistagen Therapeutics securities between April 1, 2024 and December 16, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its fasedienol drug candidate's Phase 3 success potential in the PALISADE-2 trial and downpla...

Rosen Law Firm is notifying investors in Vistagen Therapeutics who purchased stock between April 1, 2024 and December 16, 2025 of a March 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Vistagen made false and misleading statements about its drug fasedienol and the PALISADE-3 clinical trial, providing overly ...